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Heart failure is a term used to define a constellation of symptoms and signs that are 
commonly attributed to the inability of the heart to produce a cardiac output that meets the 
demands of the body. Exertional dyspnoea, peripheral oedema as well as orthopnoea are the 
usual findings following history taking and physical examination. It remains a deadly disease 
and increasingly effective treatments in modern day medicine mean that patients are living 
longer and are more likely to have multiple co-morbidities when they present to hospital. It 
affects between 1-2% of the population and is more common in the elderly; around 6-10% of 
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The term “heart failure with reduced ejection fraction” and “heart failure with preserved 
ejection fraction” describe 2 completely different diseases and underlying pathophysiology. 
Around 50% of patients with heart failure have preserved ejection fraction. However, in day 
to day clinical practice, unless explicitly stated otherwise, the use of the term heart failure is 
commonly understood to refer to heart failure with reduced ejection fraction. The reduction 
in systolic function of the left ventricle commonly results from a variety of causes. This is also 
dependent on geographical location and prevalence of other environmental risks such as 
communicable diseases, malnutrition, and low socioeconomic status. In North America and 
Western Europe, coronary artery disease remains the biggest underlying cause of heart 
failure with reduced ejection fraction (HFrEF). Whilst in Africa and Asia, rheumatic heart 
disease is still a major cause, similar to the role played by hypertension in the African-
American cohort.{ ADDIN PAPERS2_CITATIONS <citation><uuid>A31A0292-4490-4D99-94FC-
5ACD260766F4</uuid><priority>0</priority><publications><publication><volume>80</volu
me><publication_date>99200109001200000000220000</publication_date><number>2-
3</number><institution>Cardiac Medicine, National Heart &amp; Lung Institute, Imperial 
College School of Medicine, Dovehouse Street, London SW3 6LY, UK. 
g.mendez@abdn.ac.uk</institution><startpage>213</startpage><title>The epidemiological 













Physiological consequences of heart failure 
 
A reduction in ejection fraction activates a sequence of adaptive mechanisms to maintain 
adequate cardiac output. The renin-angiotensin-aldosterone system (RAAS) as well as the 
adrenergic system are activated which leads to increased left ventricular contractility and 
vasoconstriction. The resulting increase in sodium and water retention, heart rate and blood 
pressure synergistically aim to maintain adequate cardiac output. Although this 
neuroendocrine activation initially aims to meet cardiac output demand, continuous 
activation results in maladaptive cardiac remodelling and has deleterious effects on left 
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/citation>} The circulating levels of angiotensin-2 (AT-2) have been shown to increase in heart 
failure, impacting on cell function and altering intrinsic myocardial contractility, ventricular 
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tions><cites></cites></citation>} Meanwhile continuous sympathetic drive has been shown 
to result in eccentric left ventricular hypertrophy, maladaptive remodelling, and worsening 
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tions><cites></cites></citation>}. High circulating aldosterone levels were found to have an 
impact on cardiac function. This occurs through mechanisms such as magnesium/potassium 
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Contemporary heart failure therapy 
 
Based on the above hypotheses, multiple randomised controlled trials (RCTs) have been 
conducted over the last 3 decades to investigate and establish treatment for heart failure. 
Blockade of the adrenergic as well as the RAAS formed the basis of therapy. Beta-blockers 
have been shown in trials such as CIBIS-II, COPERNICUS and MERIT-HF to reduce mortality by 
up to a third.{ ADDIN PAPERS2_CITATIONS <citation><uuid>ABA34291-7FA0-4FBA-A2F0-
03D04E33EC3F</uuid><priority>0</priority><publications><publication><volume>353</vol
ume><publication_date>99199901021200000000222000</publication_date><number>914
6</number><startpage>9</startpage><title>The Cardiac Insufficiency Bisoprolol Study II 
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Prospective Randomized Cumulative Survival (COPERNICUS) Study 
Group</lastName></author></authors></publication></publications><cites></cites></citat
ion>} 
Almost a decade earlier, CONSENSUS and SOLVD investigators also confirmed the mortality 
benefit of angiotensin-converting enzyme (ACE) inhibitors when added to standard heart 
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Despite treatment with ACE inhibitors and the progress that was made, mortality from heart 
failure remained high. The concept of “aldosterone escape” led researchers to test the 
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ites></citation>} This led to the design of the RALES trial which sought to answer this question 
with the drug Spironolactone. The trial was stopped early due to marked mortality benefit in 
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The role of natriuretic peptide and neprilysin inhibition 
   
The natriuretic peptide system counteracts the effects of RAAS activation, inhibits secretion 
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publications><cites></cites></citation>} The release of brain natriuretic peptide (BNP) and 
N-terminal proBNP (NT-proBNP) promotes natriuresis and vasodilatation and occurs as a 
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publications><cites></cites></citation>} In the atrium, atrial natriuretic peptide (ANP) is also 
released as a response to atrial stretch and plays a similar role to BNP and NT-proBNP.  
 
Naturally, efforts have been made to try and manipulate this pathway to improve heart failure 
outcomes. Initial strategies have focused on two aspects; the administration of exogenous 
natriuretic peptide as well as the inhibition of its breakdown. BNP and NT-proBNP are broken 
down by neprilysin, a membrane bound endopeptidase. Disappointingly, the administration 
of the recombinant BNP nesiritide in the ASCEND-HF study which was a large randomised, 
double-blind, placebo-controlled trial did not show any mortality benefit nor did it reduce the 
rate of heart failure hospitalisations.  
 
Early attempts at neprilysin inhibition with the hope of raising the levels of natriuretic peptide 
and its activity unmasked another factor that had to be considered. Compounds such as 
racecadotril and candoxatrilat, which although were successful in raising levels of ANP, did 
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publications><cites></cites></citation>} It soon became apparent that due to the role that 
neprilysin also plays in AT-2 breakdown, lone neprilysin inhibition without concurrent 
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publications><cites></cites></citation>} The vasodilatory effects obtained were offset by the 
vasoconstriction caused by AT-2.  
 
Chemical structure, pharmacokinetics and metabolism 
 
Sacubitril/Valsartan (LCZ696) is a combined neprilysin inhibitor and AT-2 receptor blocker. Its 
empirical formula (hemipentahydrate) is C48H55N6O8Na3 2.5 H2O with a molecular mass of 
957.99. The chemical structure is shown in Figure 1. 
 
Figure { SEQ Figure \* ARABIC } - Chemical structure of Sacubitril/Valsartan (LCZ696) – owned and provided by Novartis© 
Sacubitril is a prodrug and the therapeutic effect of Sacubitril/Valsartan is partly achieved via 
the action of the active metabolite of Sacubitril, LBQ657 which inhibits neprilysin. At the same 
time, blockade of the AT-2 type 1-receptor is provided by the action of Valsartan and it is this 
concurrent inhibition of both pathways that leads to Sacubitril/Valsartan’s overall therapeutic 
effect (Figure 2). 
 
 
Figure { SEQ Figure \* ARABIC } - Mechanism of action for Sacubitril/Valsartan (LCZ696) 
    
 
In a study involving 30 selected patients who were given the drug in dosages of 100 mg twice 
daily and 200 mg twice daily, plasma concentrations of Sacubitril, LBQ657, and Valsartan 
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cites></citation>} Cmax and AUC 0-12 h for Sacubitril and LBQ657 were dose-proportional while 
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Levels of cyclic guanosine monophosphate (cGMP) in the urine and plasma as well as levels 
of ANP in the urine were increased in volunteer subjects. Plasma renin markers (plasma renin 
activity, plasma renin concentration) were significantly raised during the same period. All of 
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cites></citation>} Oral bioavailability is estimated to be around at least 60%. The terminal 
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hors></publication></publications><cites></cites></citation>} Steady state levels of 
Sacubitril/Valsartan with a twice daily dosing regimen are achieved in 3 days.   
 
Drug elimination is primarily through renal excretion in the form of the active metabolite 
LBQ657. An estimated 51-68% is excreted through the urine whilst the remainder is excreted 
through the faeces. In-vivo studies have demonstrated a low risk of inhibiting or inducing the 
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 Clinical studies 
PARAMOUNT and PARADIGM-HF 
 
The PARAMOUNT study was a phase 2, randomised, parallel-group, double-blind multicentre 
trial in patients with New York Heart Association (NYHA) class II-III symptoms and heart failure 
with preserved ejection fraction (HFpEF). This was defined as having an ejection fraction of 







l><type>400</type><title>The angiotensin receptor neprilysin inhibitor LCZ696 in heart 
failure with preserved ejection fraction: a phase 2 double-blind randomised controlled 





















ctive comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN 
fracTion (PARAMOUNT) 
Investigators</lastName></author></authors></publication></publications><cites></cites>
</citation>} Patients were assigned to receive either LCZ696, titrated to 200 mg twice daily 
or Valsartan, titrated to 160 mg twice daily. The trial was designed to investigate the safety 
and efficacy of LCZ696 in patients with HFpEF. The primary endpoint was change from 







l><type>400</type><title>The angiotensin receptor neprilysin inhibitor LCZ696 in heart 
failure with preserved ejection fraction: a phase 2 double-blind randomised controlled 





















ctive comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN 
fracTion (PARAMOUNT) 
Investigators</lastName></author></authors></publication></publications><cites></cites>
</citation>} Secondary endpoints measured were echocardiographic parameters, blood 
pressure, NYHA class, and quality of life as measured by the Kansas City Cardiomyopathy 







l><type>400</type><title>The angiotensin receptor neprilysin inhibitor LCZ696 in heart 
failure with preserved ejection fraction: a phase 2 double-blind randomised controlled 
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in the treatment of heart failure: mortality bang for your 
buck.</title><submission_date>99201508141200000000222000</submission_date><numb
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citation>} Although the initial change in NT-proBNP was significant at 12 weeks in the LCZ696 
group, this was no longer significant at 36 weeks. Despite an improvement in NYHA class, 







1111/jcpt.12363</url><type>400</type><title>Neprilysin inhibition with sacubitril/valsartan 
in the treatment of heart failure: mortality bang for your 
buck.</title><submission_date>99201508141200000000222000</submission_date><numb
er>2</number><institution>Department of Pharmacy, Indiana University Health Methodist 
Hospital, Indianapolis, IN, 
USA.</institution><subtype>400</subtype><endpage>127</endpage><bundle><publicatio











l><type>400</type><title>The angiotensin receptor neprilysin inhibitor LCZ696 in heart 
failure with preserved ejection fraction: a phase 2 double-blind randomised controlled 





















ctive comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN 
fracTion (PARAMOUNT) 
Investigators</lastName></author></authors></publication></publications><cites></cites>
</citation>} Whether some of these positive signals will translate into improved outcomes is 
unclear and currently a prospective trial (PARAGON-HF) is ongoing to address this question 
(ClinicalTrials.gov ID NCT01920711).   
 
The PARADIGM-HF trial was another trial designed to compare the effects of 
sacubitril/valsartan (LCZ696), an angiotensin receptor-neprilysin inhibitor against enalapril in 
patients with heart failure and reduced ejection fraction. It was a double-blind trial and 8442 
patients with NYHA class II – IV symptoms and an ejection fraction of at least 40% were 
randomised to either LCZ696 (at a dose of 200 mg daily) or enalapril (at a dose of 10 mg twice 
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The primary outcome was a composite of death from a cardiovascular cause or hospitalisation 
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ame>Zile</lastName></author><author><lastName>PARADIGM-HF Investigators and 
Committees</lastName></author></authors></publication></publications><cites></cites>
</citation>} There was an overwhelming mortality benefit in the LCZ696 arm and the trial had 
to be stopped early. The primary outcome had occurred in 914 (21.8%) of the patients who 
received LCZ696, compared to 1117 (26.5%) of the patients who received enalapril (hazard 
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The most frequent adverse effect seen in the study was hypotension, which was more 
common in patients given LCZ696. However, this did not cause a significant number of 
patients to discontinue the drug as there were only 36 patients (0.9%) in the LCZ696 and 29 
(0.7%) in the enalapril group who had to discontinue the drug because of hypotension.  
 
Hypotension is a risk factor for renal failure and although this has been a concern, the study 
findings suggest lower incidents of clinically relevant rise in serum creatinine and drug 
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citation>} Similarly, event rates for angioedema were reassuringly low, unlike findings from 
earlier studies of neprilysin inhibition such as the OVERTURE study where angioedema was 




number><institution>Division of Circulatory Physiology, College of Physicians and Surgeons, 
Columbia University, New York, NY 10032, USA. 
mp65@Columbia.edu</institution><startpage>920</startpage><title>Comparison of 
omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus 















ons><cites></cites></citation>} This is likely attributed to LCZ696 not inhibiting ACE or 
aminopeptidase P, two enzymes which are known to be involved in bradykinin breakdown, 
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ame>Zile</lastName></author><author><lastName>PARADIGM-HF Investigators and 
Committees</lastName></author></authors></publication></publications><cites></cites>
</citation>} A similarly notable observation is the incidence of hyperkalaemia which was seen 
to occur more frequently in the enalapril group where 236 (5.6%) patients had a serum 
potassium of more than 6 mmol/litre compared to the LCZ696 group which only saw 181 
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What is also worth noting in the PARADIGM-HF study is the higher proportion of patients on 
contemporary heart failure therapy. This is in contrast to earlier heart failure trials and 
reflects modern day practice. More than 90% of patients were on a beta blocker, at least 80% 
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</citation>} Despite what is perceived to be optimum medical therapy, LCZ696 still offered 
significant mortality benefit above and beyond standard treatment.   These findings are 
compelling and have indeed begun to change the landscape of chronic heart failure 
treatment.  
 
The future: PARADISE-MI 
 
Currently, Sacubitril/Valsartan is indicated for patients who remain symptomatic despite 
being on optimum heart failure therapy, including an optimum dose of ACE inhibitor. This can 
be defined as having a hospital admission for heart failure exacerbation or worsening 
symptoms in an outpatient setting.  
 
The next logical step however, is to investigate whether Sacubitril/Valsartan could be used at 
an earlier stage, prior to the use of an ACE inhibitor in patients who have suffered a 
myocardial infarction and therefore are at risk of heart failure. The early haemodynamic 
changes post infarction resulting from stimulation of the sympathetic nervous system, RAAS, 
and release of ANP and BNP often leads to deleterious left ventricular remodelling.  
Sacubitril/Valsartan has already proven itself to be more influential than conventional ACE 
inhibitors in altering the course of chronic heart failure patients. It is hoped that earlier 
intervention in the myocardial remodelling process post infarction will translate into better 
outcomes for patients. 
 The Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure 
Events After MI (PARADISE-MI) aims to answer this clinical question and is currently recruiting 
and the study is expected to be completed in 2020. It is a multi-centre, randomised, double-
blind, controlled trial and will evaluate the effect of Sacubitril/Valsartan titrated to a target 
dose of 200 mg twice daily against Ramipril titrated to a target dose of 5 mg twice daily in 
patients following a myocardial infarction, on top of standard post myocardial infarction 
treatment.  
 
Primary outcome will be a composite endpoint of cardiovascular death, heart failure 
hospitalisation, and outpatient heart failure (time-to-first event analysis) with evidence of left 
ventricular systolic impairment or pulmonary congestion with no previous history of chronic 
heart failure (ClinicalTrials.gov ID NCT02924727). With such promising results from 
PARADIGM-HF, it is hoped that PARADISE-MI will further offer clinicians treatment options to 
reduce the incidence of heart failure in post myocardial infarction patients and reduce 




Sacubitril/Valsartan is opening up a wealth of opportunities for patients with HFrEF. In an area 
where there has been limited pharmacological advances in the last 10 years, this is a game 
changer and a much welcomed addition to contemporary heart failure therapy. The clinical 
data is robust, and it has been proven to offer marked mortality benefit over ACE inhibitors 
in chronic heart failure patients with a good drug safety profile. Its use in patients with HFpEF 
is unclear as phase 2 trial data to date have not shown significant difference with standard 
therapy.  
 
Whether Sacubitril/Valsartan will change outcomes in the post myocardial infarction cohort 
who are at risk of developing heart failure remains to be seen, and results from PARADISE-MI 
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